RISK MANAGEMENT UPDATE

BOARD MEETING

Jacob van der Blij

30 November - 2 December 2021, Virtual Meeting





Gavi continues to pursue an ambitious strategy in a risky world with a higher risk appetite


- Gavi 5.0 is a highly aspirational strategy aiming to reach the unreached
- The COVID-19 pandemic continues to create extraordinary uncertainty and disruption both in-country and to Alliance operations
 - Risks inherently higher across the board (and subject to rapid change)
 - Monitoring and mitigation more complex with COVID restrictions and affected capacities
 - COVAX Facility and COVID-19 vaccine delivery may disrupt core mission
- COVAX Facility requires navigating uncharted territory at unprecedented speed & scale
 - Risks shifted from operational and financial to supply and delivery, and derived reputational risks
- Gavi acknowledges that many of these risks are worth taking, and it is able to do so by relying on robust risk monitoring and management



Gavi's risk profile remains stable at elevated levels

30 November - 2 December 2021

2021 residual risk exposure, taking into account existing mitigation



19 top risks prioritised

3 new COVAX risks

Absorption challenges with rapid scale up; hard to deliver / hard to plan dose donations; syringe shortages; product preferences and hesitancy

Export bans and manufacturer issues: uncertainty/competition wrt boosters, variants, mix & match; dose sharing undermining APAs

Frustration with slow pace of supply even if outside direct control; potential future delivery issues; high expectations, need for information

2 top risks decreased

No longer start-up, progress on processes, resourcing and structure; progress on financial risk mitigation and SFP 2.0 removing much risk

Progress on zero-dose data: using and sharing sub-national/geospatial data across partners, providing TA, leveraging campaigns


2 top risks increased

General increase in cyber-attacks, increase in financial resources, prominent COVID-19 player

Ongoing pandemic impact, rapid scale-up, people/processes continue to be stretched

Using Gavi's updated risk appetite statement (approved by June Board) to compare current levels of risk against






- Acknowledges risks inherent in mission and model
- Adopts an overall high risk appetite to achieve new strategy
- Defines criteria and trade-off considerations to balance risk and reward and guide context-dependent risk appetite decisions





Three risks outside of Gavi's updated risk appetite

Willingness to accept the current top risk exposures



3 risks outside of risk appetite

Not acceptable, requiring intensive mitigation efforts

14 risks just within appetite

Close to getting outside of risk appetite, requiring attention and ongoing mitigation

2 risks broadly within appetite

Acceptable, to be monitored



Recommendation

The Gavi Alliance Audit and Finance Committee <u>recommends</u> to the Gavi Alliance Board that it:

Approve the Risk & Assurance Report 2021 attached as Annex A to Doc 09.

The Gavi Alliance Board is furthermore requested to **provide guidance** on the following questions:

- a) Does the Board agree with the top risks identified this year and its ranking against likelihood and impact?
- b) Are there concerns on risk exposures **not within Gavi's risk appetite** and, if so, are further investments or different approaches to mitigation required?



THANK YOU



